Recent updates in refractory metastatic colorectal cancer management

Recent updates in refractory metastatic colorectal cancer management

Systemic Therapy in LA-SCCHN
French Subtitles Available in Video Player
Download Transcript (EN)
Download Transcript (FR)
Icon Objectives

Learning Objectives

Upon completion of this program, participants will be able to:

  1. Recognize the care gaps and unmet need of patients with unresectable LA-SCCHN
  2. Describe alternative treatments for patients with unresectable LA-SCCHN and cisplatin ineligibility
  3. Summarize emerging therapies and investigational approaches for patients with unresectable LA-SCCHN
Icon Chair Speaker

Speakers

Dr. Anna Spreafico

This program has been made possible through unrestricted support from Taiho.

Studies/trials discussed:

  • FRESCO-2 study
  • Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
  • SUNLIGHT study
  • Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study
Tagged